Utah Senate passes medical cannabis compromise, HB3001 (6th substitute), 22–4

The Utah Senate on special session approved House Bill 3001 (6th substitute), the Utah Medical Cannabis Act, sending the measure back to the House with a 22–4 roll-call vote and three senators absent.

Senator Vickers, the bill—s sponsor, described the proposal as a bipartisan, negotiated compromise developed with the governor—s office, law enforcement, patient groups and health professionals. "We wanna be able to treat a patient with a product that we feel comfortable with that the physician would feel comfortable in dosing," Vickers said, arguing the measure treats cannabis "like medicine" and emphasizes clinical oversight.

Supporters said the bill respects voters who approved Proposition 2 while creating a more regulated pathway for patient access. "Cannabis is medicine," said Senator Zender, a family physician who urged colleagues to favor clinical safeguards. Senator Davis, who also supported the measure, said it "mirrors the will of the people" and noted technical fixes would be needed but that the substitute represented an appropriate first step.

Opponents criticized both the process and some substantive features. Senator Dabakis, who offered an alternative substitute that would have decriminalized cardholder possession and removed much of the proposed regulatory apparatus, urged the Senate to "respect the will of the voters" and avoid a large new bureaucracy. Senator Bramble said Prop 2 had failed overwhelmingly in his district and argued the legislature must represent district-level outcomes: "In my senate district, proposition 2 failed by over 70%," he said.

Several senators raised practical concerns the bill does not resolve, including how revenues and retail operations will be handled under federal law. Senator Andragg asked whether federally insured banks would be able to accept deposits from medical-cannabis sales; Vickers acknowledged the bill contains no banking fix and said the state treasurer and agencies would need to address those issues, noting that retail cannabis pharmacies would likely be largely cash businesses.

The chamber considered multiple amendments aimed at adding oversight or employee protections but defeated them on the floor. Senator Escamilla sought language requiring Senate confirmation for members of a compassionate-use board and later proposed a provision to protect public employees from adverse action if they decline to participate in medical-cannabis activities; both amendment motions failed after debate.

Under suspension of the constitutional three-reading requirement the Senate read HB3001 (6th substitute) for consideration and moved to final action. The roll call produced 22 yea votes and 4 nay votes; the presiding officer said the bill "shall be signed by the president and sent to the house for the signature of the speaker." The Senate then informed the governor and the House that it had completed its business and adjourned sine die.

What the bill does and next steps: the 6th substitute establishes a regulated medical-cannabis program that sponsors described as modeled on a pharmacy-central-fill approach, authorizes private cultivators, processors, testing labs and retail pharmacies under state licensure, and includes provisions intended to align statutory language with the initiative. It does not itself resolve federal banking exposure; sponsors said that will require further legislative or administrative action. The House and governor will complete the final steps for the measure to become law.

The Senate debate highlighted deep divisions over implementation, process and the balance between honoring the initiative and ensuring clinical and legal safeguards. Lawmakers who opposed the bill warned of potential federal complications and said the public may see the legislative response as overriding voters—intent. Backers said the approach is necessary to deliver regulated medication to patients while curbing the black market.